Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology)


Creative Commons License

Inal A., Kos F. T. , Algin E., Yildiz R., Berk V., Unek I. T. , ...Daha Fazla

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, cilt.19, sa.2, ss.125-129, 2015 (ESCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Konu: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.5114/wo.2014.43933
  • Dergi Adı: WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
  • Sayfa Sayıları: ss.125-129

Özet

Aim of the study: Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of the study was to search for prognostic factors for survival in patients with gemcitabine (Gem)-refractory or with gemcitabine and cisplatin (GemCis)-refractory advanced pancreatic cancer.